Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of intravenous recombinant human plasma gelsolin for infection-related moderate-to-severe ARDS
NL-OMON60552Phase 2Recruiting
- Sponsor
- BioAegis Therapeutics
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing recombinant human plasma gelsolin + standard of care with placebo + standard of care (2 arms). Primary endpoint: All-cause mortality at Day 28. Started Feb 2025; status: recruiting.
02
Drugs
Recombinant human plasma gelsolin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NL-OMON60552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60552.